European Companies Search Engine
EU funding (€3,998,796): Illuminating new paths in heart failure therapy Hor14 Jan 2026 EU Research and Innovation programme "Horizon"
Text
Illuminating new paths in heart failure therapy
HeartVision is an ambitious high-risk, high-gain project that aims to unlock real-time, in vivo 3D microscopy of beating hearts and engineered heart tissues (EHTs) at cell-scale resolution – even deep within tissue folds. Heart failure is the leading cause of death worldwide, and today, there is no curative therapy for it. EHT transplantation offers hope, but we currently lack tools to assess its effectiveness in real time. Critical questions remain unanswered: Where do transplanted cardiomyocytes go? How do they integrate? When do they start contributing to heart function? Today, even imaging cells deep within therapy-scale EHTs is not possible - let alone in a beating heart. HeartVision will generate multiple IPs with potential in current and future clinical and biotech markets, while ensuring open access to key scientific breakthroughs. It strikes a bold balance between innovation exploitation and open science dissemination. HeartVision will realize the dream of cell-scale imaging in living organs and put it in the hands of therapy developers, reshaping how we see, study, and treat heart failure and beyond.
Funded Companies:
| Company name | Funding amount |
| Universitaetsklinikum Hamburg-Eppendorf | ? |
| Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) | €688,750 |
| Norinnova AS | €0.00 |
| Universitat de Barcelona | €599,250 |
| Universitetet I Tromsoe - Norges Arktiske Universitet | €1,911,918 |
| University of Southampton | €798,879 |
Source: https://cordis.europa.eu/project/id/101258941
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany.
